Hjem › Blærecancer › Vermont
Blærecancer kliniske forsøg i Vermont
3 studier for Blærecancer søger deltagere på steder i Vermont.
Officiel studietekst (engelsk)
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- Central Vermont Medical Center/National Life Cancer Treatment, Berlin Corners
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06770582Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- Dartmouth Cancer Center - North, Saint Johnsbury
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07061964FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Vermont Medical Center, Burlington
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT05614739Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.